Capmatinib

Capmatinib is an ATP competitive inhibitor of c-MET kinase or hepatocyte growth factor receptor (HGFR). Binding of Hepatocyt Growth Factor to c-MET receptor causes activation of multiple downstream pathways. Capmatinib potently inhibits in vitro kinase activity with an IC₅₀ of 0.13 nM. It prevents HGF-stimulated H441 cell migration with an IC₅₀ value of a ~2 nM. It inhibts c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.